Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Pain and Headache Reports
Erschienen in: Current Pain and Headache Reports 12/2023

02.12.2023 | Chronic Pain Medicine (A Kaye, Section Editor)

Medical Cannabis and Its Efficacy/Effectiveness for the Treatment of Low-Back Pain: a Systematic Review

verfasst von: Cerina Lee, Elizabeth C. Danielson, Molly Beestrum, Dean T. Eurich, Ashley Knapp, Neil Jordan

Erschienen in: Current Pain and Headache Reports | Ausgabe 12/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This systematic review aims to inform the current state of evidence about the efficacy and effectiveness of medical cannabis use for the treatment of LBP, specifically on pain levels and overall opioid use for LBP. Searches were conducted in MEDLINE (PubMed), Embase, and CINAHL. The search was limited to the past 10 years (2011-2021). Study inclusion was determined by the critical appraisal process using the Joanna Briggs Institute framework. Only English language articles were included. Participant demographics included all adult individuals with LBP who were prescribed medical cannabis for LBP and may be concurrently using opioids for their LBP. Study quality and the risk of bias were both evaluated. A narrative synthesis approach was used.

Recent Findings

A total of twelve studies were included in the synthesis: one randomized controlled trial (RCT), six observational studies (one prospective, four retrospective, and one cross-over), and five case studies. All study results, except for the RCT, indicated a decrease in LBP levels or opioid use over time after medical cannabis use. The RCT reported no statistically significant difference in LBP between cannabis and placebo groups.

Summary

Low back pain (LBP) affects 568 million people worldwide. In the United States, LBP treatment represents more than half of regular opioid users. With the opioid epidemic, alternative methods, particularly medical cannabis, is now increasingly sought by practicing physicians and patients. Due to its infancy, there is minimal high-quality evidence to support medical cannabis use as a first line treatment for LBP.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Angst F, Angst J, Ajdacic-Gross V, Aeschlimann A, Rössler W. Epidemiology of back pain in young and middle-aged adults: a longitudinal population cohort survey from age 27–50 years. Psychosomatics. 2017;58(6):604–13.PubMedCrossRef
2.
Casiano VE, Dydyk AM, Varacallo M. Back Pain. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2021, StatPearls Publishing LLC. 2021.
3.
Allegri M, Montella S, Salici F, Valente A, Marchesini M, Compagnone C, et al. Mechanisms of low back pain: a guide for diagnosis and therapy. F1000Res. 2016;5.
4.
5.
Relieving pain in america: a blueprint for transforming prevention, care, education, and research. Washington (DC). 2011.
6.
• Rubinstein SM, de Zoete A, van Middelkoop M, Assendelft WJJ, de Boer MR, van Tulder MW. Benefits and harms of spinal manipulative therapy for the treatment of chronic low back pain: systematic review and meta-analysis of randomised controlled trials. BMJ. 2019;364:l689. A systematic review on current modalities for low back pain treatment and management.PubMedPubMedCentralCrossRef
7.
8.
9.
Kolber MR, Ton J, Thomas B, Kirkwood J, Moe S, Dugré N, et al. PEER systematic review of randomized controlled trials: management of chronic low back pain in primary care. Can Fam Physician. 2021;67(1):e20–30.PubMedPubMedCentralCrossRef
10.
Chou R, Wagner J, Ahmed AY, Blazina I, Brodt E, Buckley DI, et al. Treatments for acute pain: a systematic review. Rockville (MD). 2020.
11.
Abdel Shaheed C, Maher CG, Williams KA, Day R, McLachlan AJ. Efficacy, tolerability, and dose-dependent effects of opioid analgesics for low back pain: a systematic review and meta-analysis. JAMA Intern Med. 2016;176(7):958–68.PubMedCrossRef
12.
Krebs EE, Gravely A, Nugent S, Jensen AC, DeRonne B, Goldsmith ES, et al. Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: the SPACE randomized clinical trial. JAMA. 2018;319(9):872–82.PubMedPubMedCentralCrossRef
13.
Lee SW, Shen J, Kim SJ, Chun SY, Kim P, Riaz J, et al. US trends of opioid-use disorders and associated factors among hospitalized patients with spinal conditions and treatment from 2005 to 2014. Spine. 2020;45(2):124–33.PubMedCrossRef
14.
Nicol AL, Hurley RW, Benzon HT. Alternatives to opioids in the pharmacologic management of chronic pain syndromes: a narrative review of randomized, controlled, and blinded clinical trials. Anesth Analg. 2017;125(5):1682–703.PubMedPubMedCentralCrossRef
15.
Lee C, Lin M, Martins KJB, Dyck JRB, Klarenbach S, Richer L, et al. Opioid use in medical cannabis authorization adult patients from 2013 to 2018: Alberta, Canada. BMC Public Health. 2021;21(1):843.PubMedPubMedCentralCrossRef
16.
Safakish R, Ko G, Salimpour V, Hendin B, Sohanpal I, Loheswaran G, et al. Medical cannabis for the management of pain and quality of life in chronic pain patients: a prospective observational study. Pain Med. 2020;21(11):3073–86.PubMedCrossRef
17.
Okusanya BO, Asaolu IO, Ehiri JE, Kimaru LJ, Okechukwu A, Rosales C. Medical cannabis for the reduction of opioid dosage in the treatment of non-cancer chronic pain: a systematic review. Systematic Reviews. 2020;9(1).
18.
Montero-Oleas N, Arevalo-Rodriguez I, Nunez-Gonzalez S, Viteri-Garcia A, Simancas-Racines D. Therapeutic use of cannabis and cannabinoids: an evidence mapping and appraisal of systematic reviews. BMC Complement Med Ther. 2020;20(1):12.PubMedPubMedCentralCrossRef
19.
Pratt M, Stevens A, Thuku M, Butler C, Skidmore B, Wieland LS, et al. Benefits and harms of medical cannabis: a scoping review of systematic reviews. Syst Rev. 2019;8(1):320.PubMedPubMedCentralCrossRef
20.
Khan SP, Pickens TA, Berlau DJ. Perspectives on cannabis as a substitute for opioid analgesics. Pain Manag. 2019;9(2):191–203.PubMedCrossRef
21.
• Lucas P, Boyd S, Milloy MJ, Walsh Z. Cannabis significantly reduces the use of prescription opioids and improves quality of life in authorized patients: results of a large prospective study. Pain Med. 2021;22(3):727–39. A recent study on medical cannabis and opioid use.PubMedCrossRef
22.
Takakuwa KM, Sulak D. A survey on the effect that medical cannabis has on prescription opioid medication usage for the treatment of chronic pain at three medical cannabis practice sites. Cureus. 2020;12(12):e11848.PubMedPubMedCentral
23.
Shah A, Hayes CJ, Lakkad M, Martin BC. Impact of medical marijuana legalization on opioid use, chronic opioid use, and high-risk opioid use. J Gen Intern Med. 2019;34(8):1419–26.PubMedPubMedCentralCrossRef
24.
Barry AR, Chris CE. Treatment of chronic noncancer pain in patients on opioid therapy in primary care: a retrospective cohort study. Can Pharm J (Ott). 2020;153(1):52–8.PubMedCrossRef
25.
Orhurhu V, Urits I, Olusunmade M, Olayinka A, Salisu Orhurhu M, Uwandu C, et al. Cannabis use in hospitalized patients with chronic pain. Adv Ther. 2020;37(8):3571–83.PubMedPubMedCentralCrossRef
26.
27.
• First L, Douglas W, Habibi B, Singh JR, Sein MT. Cannabis use and low-back pain: a systematic review. Cannabis Cannabinoid Res. 2020;5(4):283–9. A systematic review on general cannabis use and low back pain.PubMedPubMedCentralCrossRef
28.
Kim TE, Townsend RK, Branch CL, Romero-Sandoval EA, Hsu W. Cannabinoids in the treatment of back pain. Neurosurgery. 2020;87(2):166–75.PubMedCrossRef
29.
Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160.PubMedPubMedCentralCrossRef
30.
Training C. Cochrane handbook for systematic reviews of interventions. 2022.
31.
32.
33.
34.
35.
Eskander JP, Spall J, Spall A, Shah RV, Kaye AD. Cannabidiol (CBD) as a treatment of acute and chronic back pain: a case series and literature review. J Opioid Manag. 2020;16(3):215–8.PubMedCrossRef
36.
37.
Toor J, Kars M, Deygoo J, Dowling O, Hameed A. Medical marijuana and the discontinuation of opioids in a patient with neuropathic chronic pain. Reg Anesth Pain Med. 2017;42(6).
38.
Zarabian K, Wannon A, Chin M, Kogan M. The intersection between integrative medicine and neuropathic pain: a case report. Explore (NY). 2021.
39.
Yeung B, Patel P, Nelson A, Dayal R. Cannabidiol in the geriatric population: a novel treatment option for chronic back pain. Pain Physician. 2018;21(3):E294.
40.
Takakuwa KM, Hergenrather JY, Shofer FS, Schears RM. The impact of medical cannabis on intermittent and chronic opioid users with back pain: how cannabis diminished prescription opioid usage. Cannabis Cannabinoid Res. 2020;5(3):263–70.PubMedPubMedCentralCrossRef
41.
Vigil JM, Stith SS, Adams IM, Reeve AP. Associations between medical cannabis and prescription opioid use in chronic pain patients: a preliminary cohort study. PLoS ONE. 2017;12(11):e0187795.PubMedPubMedCentralCrossRef
42.
Mondello E, Quattrone D, Cardia L, Bova G, Mallamace R, Barbagallo AA, et al. Cannabinoids and spinal cord stimulation for the treatment of failed back surgery syndrome refractory pain. J Pain Res. 2018;11:1761–7.PubMedPubMedCentralCrossRef
43.
Ueberall MA, Essner U, Mueller-Schwefe GH. Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German Pain e-Registry. J Pain Res. 2019;12:1577–604.PubMedPubMedCentralCrossRef
44.
Haroutounian S, Ratz Y, Ginosar Y, Furmanov K, Saifi F, Meidan R, et al. The effect of medicinal cannabis on pain and quality-of-life outcomes in chronic pain: a prospective open-label study. Clin J Pain. 2016;32(12):1036–43.PubMedCrossRef
45.
Yassin M, Oron A, Robinson D. Effect of adding medical cannabis to analgesic treatment in patients with low back pain related to fibromyalgia: an observational cross-over single centre study. Clin Exp Rheumatol. 2019;37 Suppl 116(1):13–20.
46.
Bebee B, Taylor DM, Bourke E, Pollack K, Foster L, Ching M, et al. The CANBACK trial: a randomised, controlled clinical trial of oral cannabidiol for people presenting to the emergency department with acute low back pain. Med J Aust. 2021;214(8):370–5.PubMedCrossRef
47.
Miller NS, Ipeku R, Oberbarnscheidt T. A review of cases of marijuana and violence. Int J Environ Res Public Health. 2020;17(5).
48.
49.
Memedovich KA, Dowsett LE, Spackman E, Noseworthy T, Clement F. The adverse health effects and harms related to marijuana use: an overview review. CMAJ Open. 2018;6(3):E339–46.PubMedPubMedCentralCrossRef
50.
Simpson AK, Magid V. Cannabis use disorder in adolescence. Child Adolesc Psychiatr Clin N Am. 2016;25(3):431–43.PubMedCrossRef
51.
52.
Lu HC, Mackie K. An introduction to the endogenous cannabinoid system. Biol Psychiatry. 2016;79(7):516–25.PubMedCrossRef
53.
McGolrick D, Frey N. Nabilone for chronic pain management: a review of clinical effectiveness and guidelines - an update. Ottawa (ON). 2018.
54.
Zou S, Kumar U. Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. Int J Mol Sci. 2018;19(3).
55.
Hossain MZ, Ando H, Unno S, Kitagawa J. Targeting peripherally restricted cannabinoid receptor 1, cannabinoid receptor 2, and endocannabinoid-degrading enzymes for the treatment of neuropathic pain including neuropathic orofacial pain. Int J Mol Sci. 2020;21(4).
56.
Donvito G, Nass SR, Wilkerson JL, Curry ZA, Schurman LD, Kinsey SG, et al. The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain. Neuropsychopharmacology. 2018;43(1):52–79.PubMedCrossRef
57.
Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford). 2006;45(1):50–2.PubMedCrossRef
58.
Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain. 2004;112(3):299–306.PubMedCrossRef
59.
Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain. 2007;133(1–3):210–20.PubMedCrossRef
60.
Notcutt W, Price M, Miller R, Newport S, Phillips C, Simmons S, et al. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 “N of 1” studies. Anaesthesia. 2004;59(5):440–52.PubMedCrossRef
61.
Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil. 2003;17(1):21–9.PubMedCrossRef
62.
Huggins JP, Smart TS, Langman S, Taylor L, Young T. An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain. 2012;153(9):1837–46.PubMedCrossRef
63.
International HR. The global state of harm reduction 2020. Aldgate, London, United Kingdom. 2020.
64.
Azadfard M, Huecker MR, Leaming JM. Opioid addiction. StatPearls. Treasure Island (FL). 2021.
65.
Belzak L, Halverson J. The opioid crisis in Canada: a national perspective. Health Promot Chronic Dis Prev Can. 2018;38(6):224–33.PubMedCrossRef
66.
Coussens NP, Sittampalam GS, Jonson SG, Hall MD, Gorby HE, Tamiz AP, et al. The opioid crisis and the future of addiction and pain therapeutics. J Pharmacol Exp Ther. 2019;371(2):396–408.PubMedPubMedCentralCrossRef
67.
The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. Washington (DC). 2017.
68.
Allan GM, Finley CR, Ton J, Perry D, Ramji J, Crawford K, et al. Systematic review of systematic reviews for medical cannabinoids: pain, nausea and vomiting, spasticity, and harms. Can Fam Physician. 2018;64(2):e78–94.PubMedPubMedCentral
69.
Lee C, Round JM, Klarenbach S, Hanlon JG, Hyshka E, Dyck JRB, et al. Gaps in evidence for the use of medically authorized cannabis: Ontario and Alberta, Canada. Harm Reduct J. 2021;18(1):61.PubMedPubMedCentralCrossRef
Metadaten
Titel
Medical Cannabis and Its Efficacy/Effectiveness for the Treatment of Low-Back Pain: a Systematic Review
verfasst von
Cerina Lee
Elizabeth C. Danielson
Molly Beestrum
Dean T. Eurich
Ashley Knapp
Neil Jordan
Publikationsdatum
02.12.2023
Verlag
Springer US
Erschienen in
Current Pain and Headache Reports / Ausgabe 12/2023
Print ISSN: 1531-3433
Elektronische ISSN: 1534-3081
DOI
https://doi.org/10.1007/s11916-023-01189-0

Neu im Fachgebiet AINS

Mit dem Seitenschneider gegen das Reißverschluss-Malheur

03.06.2024 Urologische Notfallmedizin Nachrichten

Wer ihn je erlebt hat, wird ihn nicht vergessen: den Schmerz, den die beim Öffnen oder Schließen des Reißverschlusses am Hosenschlitz eingeklemmte Haut am Penis oder Skrotum verursacht. Eine neue Methode für rasche Abhilfe hat ein US-Team getestet.

Schlaganfall: Frühzeitige Blutdrucksenkung im Krankenwagen ohne Nutzen

31.05.2024 Apoplex Nachrichten

Der optimale Ansatz für die Blutdruckkontrolle bei Patientinnen und Patienten mit akutem Schlaganfall ist noch nicht gefunden. Ob sich eine frühzeitige Therapie der Hypertonie noch während des Transports in die Klinik lohnt, hat jetzt eine Studie aus China untersucht.

Reanimation bei Kindern – besser vor Ort oder während Transport?

29.05.2024 Reanimation im Kindesalter Nachrichten

Zwar scheint es laut einer Studie aus den USA und Kanada bei der Reanimation von Kindern außerhalb einer Klinik keinen Unterschied für das Überleben zu machen, ob die Wiederbelebungsmaßnahmen während des Transports in die Klinik stattfinden oder vor Ort ausgeführt werden. Jedoch gibt es dabei einige Einschränkungen und eine wichtige Ausnahme.

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren
Bildnachweise